Gonzaga head coach Mark Few preached it to the choir almost every other game. The national media and college basketball decided to look the other way instead. B ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Latinos have become increasingly concerned about how weight gain affects their health. Beyond abuelas and tias pushing them to eat more tamales at family gatherings, or being criticized about the size ...

A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s obesity drug Zepbound lost nearly 50% more weight than those using rival ...

Novo Nordisk said it did not ask or pay to block Zepbound, contending that the exclusion was entirely Caremark’s decision. “We believe it’s in the best interest of patients and physicians ...

Zepbound (tirzepatide) is a once-a-week injectable weight-loss medication. It helps reduce your appetite by influencing two hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent ...

There may be ways you can get your insurance plan to cover Zepbound if it doesn’t already. The best way to find out whether your insurance company covers Zepbound is by calling your provider ...